AI
Commented by Nico Popp on September 4th, 2025 | 07:25 CEST
AI reaches medicine – Here is where it has the greatest impact: NetraMark, Siemens Healthineers, Intuitive Surgical
AI is revolutionizing more and more industries. A recent article in Handelsblatt highlights the enormous potential in medicine and names Siemens Healthineers and Intuitive Surgical as the beneficiaries. AI would significantly increase the often-lacking efficiency in industry. According to Handelsblatt, citing analysts from Fortune Business Insights, the market for AI in healthcare could grow by 44% annually to USD 504 billion by 2032. We show where the greatest leverage exists and which companies are still small enough to benefit disproportionately from developments in the coming years.
Read
Commented by Nico Popp on September 1st, 2025 | 07:05 CEST
The key to higher returns: How ESG is making Newmont, Intel, and Almonty more successful
Just a few years ago, ESG was a buzzword that companies in industry and mining could use to present themselves in a favorable light. Today, standards for sustainable business practices are clearly defined and bring tangible benefits to all who adhere to them. For example, cooperation with local residents and adherence to high environmental standards at mining companies such as Newmont and Almonty ensure better financing conditions and motivated, skilled workers. Potential customers such as Intel also pay close attention to the conditions under which raw materials are extracted. In this article, we explain how ESG and returns go hand in hand.
Read
Commented by Fabian Lorenz on August 27th, 2025 | 07:20 CEST
Quick 30% return possible? Novo Nordisk, D-Wave, and NetraMark shares!
Three completely different companies, but all with return potential: AI specialist NetraMark is on the verge of a technical breakout. NetraAI has outperformed ChatGPT and DeepSeek and is gaining more customers. If the breakout occurs, the stock could quickly move toward the analyst price target, representing a potential gain of around 30%. At Novo Nordisk, last week's price gains have almost been lost again. Wegovy's strong market entry in South Korea caused only brief jubilation. Now, competition from Eli Lilly is dampening the mood. At D-Wave, the stock could soon be heading toward new highs again. The Company plans to accelerate its growth in Asia, and new momentum for the stock is expected in September.
Read
Commented by Armin Schulz on August 26th, 2025 | 07:10 CEST
The blueprint for AI-driven drug discovery: How Evotec, NetraMark Holdings, and BioNTech are leveraging new opportunities
The pharmaceutical industry is undergoing a revolution. Artificial intelligence is reducing drug discovery times from years to months and dramatically increasing hit rates. Data-driven predictions and virtual simulations are increasingly replacing costly trial-and-error approaches. This technological leap is already generating concrete successes and massive competitive advantages for pioneers who implemented their digitalization strategies early on. Most recently, an AI-designed drug advanced to clinical trials in record time. Three companies driving this change and reaping its benefits are Evotec, NetraMark Holdings, and BioNTech.
Read
Commented by André Will-Laudien on August 21st, 2025 | 07:15 CEST
High-tech correction! A brief pause, then the party continues at Palantir, Deutsche Telekom, MiMedia, and SAP
Oops – there it is. The first correction at Palantir was somewhat severe. But after a 1000% increase in 24 months – who cares? The blockbuster themes of artificial intelligence, cloud computing, and big data continue to dominate the stock market, leading to significant daily price gains. Investors seem to view the capital markets as an almost one-way success story in which valuations play hardly any role. Europe is increasingly taking the lead, with the EURO STOXX 50 rising by around 20% since the tariff dip in April. Despite apparent risks, many investors are sticking to the bull market, although the S&P 500's high Shiller P/E ratio of over 38 is sending out a clear warning signal. Deutsche Telekom is generating excitement with the announcement of another innovation push in the form of its first AI-based smartphone. The coming weeks therefore offer exciting opportunities for investors who, despite the warning signs, are betting on the continued momentum of the market. Where to invest?
Read
Commented by André Will-Laudien on August 21st, 2025 | 07:05 CEST
The AI revolution is turning biotech into a gold mine! BioNTech, Eli Lilly, NetraMark Holdings, and Pfizer know how!
Artificial intelligence (AI) is becoming increasingly important in drug research and is revolutionizing the development of new active ingredients. Machine learning and neural networks enable large amounts of data to be analyzed and potential drugs to be identified more quickly. AI also plays a central role in the planning and execution of clinical trials by recognizing data patterns, identifying suitable patients, and thus increasing the chances of success. The market for AI in drug development is growing rapidly. Experts estimate it will reach several billion US dollars by 2025, with projected annual growth of over 40%. Where are the opportunities and risks for agile investors?
Read
Commented by Stefan Feulner on August 19th, 2025 | 07:20 CEST
JD.com, NetraMark, Palantir – Opportunities in the second tier
The extremely high valuations of the big players in artificial intelligence are a thorn in the side of many analysts. The sharp rise in share prices of Nvidia and Palantir, the latter of which has already reached dot-com status with a current price-to-earnings ratio of no less than 242, means that a healthy consolidation is long overdue. In contrast, AI companies from the second and third tier are standing out, whose potential has so far been largely overlooked by investors.
Read
Commented by Armin Schulz on August 19th, 2025 | 07:15 CEST
TUI, naoo, Puma – Three stocks whose digital revolution could double your portfolio
If you are not thinking digitally today, you are losing out. Period. Progressive companies do not just use AI and data; they link them to their core business. The result? Less friction, more room for growth, and customers who come back. These companies are not only leaving the competition behind, but they are also becoming magnets for savvy investors. Let's take a closer look at how TUI, naoo, and Puma are intelligently using their data, AI, and platforms to make their businesses fit for the future.
Read
Commented by Nico Popp on August 14th, 2025 | 07:10 CEST
High flyers are emerging here: NetraMark, Bechtle, Adesso
Sometimes you need an outside opinion. Consulting firms have been cashing in on this for decades. Especially when it comes to new technologies, fresh external input makes sense. McKinsey consultants estimate that the rapid deployment of modern technology alone can lead to productivity gains of 3% - year after year. No wonder, then, that external service providers are in demand in an increasing number of industries and are creating added value. We explain the opportunities these companies can offer investors.
Read
Commented by Nico Popp on August 11th, 2025 | 07:15 CEST
Platform strategies are shaking up the biotech market: BioNxt, Thermo Fisher Scientific, Evotec
In biotech, the all-or-nothing principle no longer applies. Instead of offering just one product, the platform economy is becoming the norm in the development of tomorrow's active ingredients. What does this mean? Companies are working together, sharing their technology, and thereby reducing their dependence on individual projects. Since each player can focus on its core competencies, new active ingredients are brought to market faster, and even innovations in niche areas can gain significant traction thanks to strong partners. We explain what platform economics means in the biotech sector and how investors can benefit from it.
Read